Gilead Sciences, Inc.

North Carolina State University

Carna Biosciences, Inc.

Yasamin Moazami

Leena Patel

Suet Chung Yeung

Julian Andrew Codelli

Kevin S Currie

Jayaraman Chandrasekhar

Peter A Blomgren

Jeffrey E Kropf

Jennifer Anne Treiberg

Zhongdong Zhao

Christopher T Clark

Stephane Perreault

Kirk L Stevens

Jason K Perry

Natalie Seeger

Nicole Nava

Taryn Campbell

Kassandra F Sedillo

Michael Graupe

Juan A Guerrero

Tetsuya Kobayashi

Jie Xu

Stephen D Holmbo

Jesse M Jacobsen

Heath A Weaver

Suet C Yeung

Julian A Codelli

Scott E Lazerwith

Michael L Mitchell

Scott D Schroeder

Eda Y Canales

Jonathan William Medley

Stephen E Ammann

Qingming Zhu

Daniel G Shore

Weng K Chang

Henok H Kinfe

Seung H Lee

Masaaki Sawa

Juan Guerrero

Patrick J Salvo

Joshua G Pierce

Christopher J Swank

Gavin Williams

Hirokazu Matsumoto

Mai Arai

Ryoko Nakai

Thomas J Paul

David L Kukla

Jonah J Chang

Philip L Loziuk

Latesh Lad

Eric Hu

Catherine Pugh

David C Muddiman

Will Watkins

Jesse Jacobsen

Stephen Holmbo

Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.

PARP7 inhibitors

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Thienopyrrole compounds

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Quinoline derivatives

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

Diacylglycerol kinase modulating compounds

Diacylglyercol kinase modulating compounds

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

Compounds for inhibition of &#x3b1;4 &#x3b2;7 integrin

Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify &#x3b2;-N-methylamino-L-alanine (BMAA) in a sample. The reagents can be used as stable isotope labeled standards in analytical methods, including in conjunction with mass spectrometry, to detect and/or quantify BMAA in a sample, such as a protein sample from a subject.

Materials and methods for detection and quantification of &#x3b2;-N-methylamino-L-alanine

Compounds for inhibition of alpha 4 beta 7 integrin

Compounds for inhibition of &#x3b1;4&#x3b2;7 integrin

Imidazopyridine derivatives

Growing community of inventors

Seattle, WA, United States of America

Yasamin Moazami